Healthcare
Diagnostics & Research
$26.13B
17.3K
Key insights and themes extracted from this filing
Net earnings for the three months ended June 30, 2025, decreased by 8.78% to $202.3 million from $221.8 million in the prior year period, even as total net sales increased by 3.85% to $983.2 million from $946.8 million. This decline is primarily attributable to a significantly higher provision for taxes and gross margin pressure.
Gross profit as a percentage of net sales decreased to 59.0% for the three months ended June 30, 2025, from 59.7% in the prior year, and to 59.2% from 59.5% for the six months. This pressure reflects increased tariff costs and unfavorable business mix, partially offset by favorable price realization and benefits from the SternDrive program.
The provision for taxes more than doubled to $46.3 million (18.6% tax rate) for the three months ended June 30, 2025, from $21.4 million (8.8% tax rate) in 2024. For the six-month period, the tax provision increased by 31.46% to $84.7 million (18.8% tax rate) from $64.4 million (13.9% tax rate), largely due to the absence of a non-cash discrete tax benefit recognized in the prior year.